Trial Profile
A Randomized, Double-blind Controlled Study to Determine the Effectiveness, Safety and Tolerability of Actorif(R) Compared to Rebif(R) in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2016
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 14 Jul 2014 Recruitment is expected to complete on 21 July 2015.
- 14 Jul 2014 New trial record